What is brensocatib for bronchiectasis?

Bronchiectasis causes widened, damaged airways that can collect mucus and become inflamed. Brensocatib is designed to reduce activity of enzymes released by certain inflammatory cells, with the aim of reducing airway inflammation and flare-ups. It does not reverse established airway widening and is not a replacement for airway-clearance techniques, vaccinations, antibiotics when prescribed, or treatment of an underlying cause. The evidence and regulatory status can vary by location, so a respiratory clinician should explain whether it is an option.

Ask your respiratory team what treatment goal is being considered and how it fits with your current plan. Bring details of cough, phlegm, previous flare-ups, allergies, dental or skin problems, and all medicines. Do not start, stop, or share brensocatib. Your clinician may review sputum, breathing tests such as spirometry, and imaging such as a chest X-ray before changing long-term care. Continue the airway-clearance plan you have been taught unless advised otherwise.

Contact your care team promptly for a clear increase in cough or phlegm, a change in phlegm colour, fever, worsening breathlessness, chest pain, or coughing blood. Seek emergency help for severe breathing difficulty, blue lips, confusion, fainting, or more than a small streak of blood. Report new rash, swelling, severe stomach symptoms, or other concerning effects after a medicine.

Ask whether brensocatib is authorised or available for your situation, what benefits and side effects are expected, which monitoring is needed, and what alternatives may reduce flare-ups. Ask how to recognise an infection and when to use your action plan.